After the Nasdaq sets a seven-year record, a slew of high flying stocks report in the coming week. Plus there's a bonus day from Tesla.

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Cipla has now entered into obesity Market with a partnership with Eli Lilly for Tirzepatide (GLP-1) is exclusive to the ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also ...

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...